Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:5/23/2013)... 23, 2013  Net Medical Xpress Solutions, Inc., (OTC ... today the company has signed a letter of intent ... in Huntsville, AL . MedTel Solutions ... staffing and recruitment of telemedicine physicians. Consideration for the ... agreement, which is expected by June 30, 2013. ...
(Date:5/23/2013)... , May 23, 2013  CAS Medical Systems, Inc. (NASDAQ: ... for non-invasive patient monitoring, today announced that Thomas ... present at the 2 nd Annual Marcum MicroCap Conference ... in New York City . ... in the Estate 10 room and will be available via ...
(Date:5/23/2013)...  Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) ... development and commercialization of novel bile acid therapeutics to ... today announced that Mark Pruzanski , ... the Deutsche Bank Securities 38th Annual Health Care Conference ... 29, 2013 at 4:10 p.m. ET. About ...
Breaking Medicine Technology:Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2
... April 29 Today is an exciting day for ... ones who are profoundly affected. Today a new prostate cancer treatment option, ... , , ... excited to see this innovative treatment option made available for patients with ...
... South Korea , April 29 OrbusNeich today announced that ... final 12-month clinical results of the global e-HEALING Registry confirmed that the ... in this high-risk patient group. , ... The data were presented by Dr. Andres Iniguez , M.D., ...
Cached Medicine Technology:Advanced Prostate Cancer Patients Finally Have Another Option 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients 3
(Date:5/23/2013)... 2013 Dr. Katherine Ahn is ... in Orange County, OCCares , will hold its first ... The event details are as follows: , Sunday May 26th, ... Clinton Street, Garden Grove, CA 92843 , The benefit celebration ... Christian vocalists Charmaine & Jonathan Thulin. There will also ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
(Date:5/23/2013)... Click here to read the full ... increasingly seeing their success develop through merger and ... according to new research carried out by MaRS , ... has compiled its research into a series of articles ... research have shown the general trend that the success ...
(Date:5/23/2013)... Jeanne Ettelson, president of Beyond OCD ... only free OCD support group in Chicago. Launched ... sufferers, the group is lead by psychologists who specialize ... allows group participants to learn accurate information about OCD, ... “Participants in Beyond OCD’s support group benefit from ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Cheap Concert Tickets ... the Summer of 2013 at stadiums throughout North America. ... board on Paul McCartney concert tickets to help McCartney fans ... of Cheap Concert Tickets, states that she is also offering ... concert tickets. Being a baby boomer, she is also ...
Breaking Medicine News(10 mins):Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2
... allergic to fish and shellfish and self-reported, physician diagnosed ... 2.3 percent of the general population, which is about ... researchers found about 2.3 percent of people in the ... Researchers interviewed more than 5,500 households to determine the ...
... the Coalition of Health for Asthmatics in Sports and Exercise and ... // to 127, 6- to 18-year olds who had ... by a 10-item questionnaire. The most common risk factor noted by ... exercise test, kids ran for eight to 10 minutes. Forced expiratory ...
... Germany researchers shows young breast cancer survivors may suffer ... patients may not be getting the appropriate therapy needed ... ,Researchers sampled nearly 200 breast cancer patients who had ... physical symptoms and current therapy treatments. Results showed that ...
... is the most frequent and distressing problem related to ... and has profound // effects on a patient’s ability ... or years. New research finds energy conservation and activity ... through drug therapy. ,Energy conservation is the ...
... a third of American adults are obese, up from 14 ... few // prescription weight-control drugs are on the market, and ... or by preventing the body from digesting and absorbing fats. ... with mice that when the enzyme AMPK (AMP-activated protein kinase, ...
... An estimated 2.7 million people in the United States ... as chronic olfactory dysfunction. // Head trauma, viral infection, ... or normal aging can cause chronic olfactory dysfunction. ... or smell, you know how different you feel. Some ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: